JPWO2021044379A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021044379A5
JPWO2021044379A5 JP2022514833A JP2022514833A JPWO2021044379A5 JP WO2021044379 A5 JPWO2021044379 A5 JP WO2021044379A5 JP 2022514833 A JP2022514833 A JP 2022514833A JP 2022514833 A JP2022514833 A JP 2022514833A JP WO2021044379 A5 JPWO2021044379 A5 JP WO2021044379A5
Authority
JP
Japan
Prior art keywords
mhc
cells
hla
nucleotide sequence
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022514833A
Other languages
English (en)
Japanese (ja)
Other versions
JP7753197B2 (ja
JP2022547505A5 (https=
JP2022547505A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/058281 external-priority patent/WO2021044379A1/en
Publication of JP2022547505A publication Critical patent/JP2022547505A/ja
Publication of JP2022547505A5 publication Critical patent/JP2022547505A5/ja
Publication of JPWO2021044379A5 publication Critical patent/JPWO2021044379A5/ja
Priority to JP2025117434A priority Critical patent/JP2025170191A/ja
Application granted granted Critical
Publication of JP7753197B2 publication Critical patent/JP7753197B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022514833A 2019-09-05 2020-09-04 ユニバーサルドナー細胞 Active JP7753197B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025117434A JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962896473P 2019-09-05 2019-09-05
US62/896,473 2019-09-05
US202062979771P 2020-02-21 2020-02-21
US62/979,771 2020-02-21
PCT/IB2020/058281 WO2021044379A1 (en) 2019-09-05 2020-09-04 Universal donor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025117434A Division JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Publications (4)

Publication Number Publication Date
JP2022547505A JP2022547505A (ja) 2022-11-14
JP2022547505A5 JP2022547505A5 (https=) 2023-09-11
JPWO2021044379A5 true JPWO2021044379A5 (https=) 2023-09-11
JP7753197B2 JP7753197B2 (ja) 2025-10-14

Family

ID=72473593

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514833A Active JP7753197B2 (ja) 2019-09-05 2020-09-04 ユニバーサルドナー細胞
JP2025117434A Pending JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025117434A Pending JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Country Status (13)

Country Link
US (5) US11104918B2 (https=)
EP (1) EP4025690A1 (https=)
JP (2) JP7753197B2 (https=)
KR (1) KR20220052370A (https=)
CN (1) CN114375300A (https=)
AU (1) AU2020341186A1 (https=)
BR (1) BR112022004026A2 (https=)
CA (1) CA3150235A1 (https=)
CO (1) CO2022002586A2 (https=)
IL (1) IL291044A (https=)
MX (1) MX2022002783A (https=)
PH (1) PH12022550543A1 (https=)
WO (1) WO2021044379A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
KR20220058579A (ko) 2019-09-05 2022-05-09 크리스퍼 테라퓨틱스 아게 보편적 공여자 세포
US11104918B2 (en) 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells
KR20230146007A (ko) 2020-12-31 2023-10-18 크리스퍼 테라퓨틱스 아게 범용 공여자 세포
AU2022283291A1 (en) * 2021-05-27 2023-11-02 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2023183313A1 (en) * 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
CN116732099B (zh) * 2023-08-07 2023-11-24 北赛泓升(北京)生物科技有限公司 一种干细胞多重CRISPR/Cas基因组编辑方法
WO2025202874A1 (en) 2024-03-25 2025-10-02 Crispr Therapeutics Ag Genetically modified cells expressing glp-1 receptor agonist
WO2026069163A1 (en) 2024-09-25 2026-04-02 Crispr Therapeutics Ag Differentiation method for producing immature beta cells

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US20060222633A1 (en) 2000-05-11 2006-10-05 Yale University Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host
WO2003014313A2 (en) 2001-08-06 2003-02-20 Bresagen, Ltd. Alternative compositions and methods for the culture of stem cells
US7541185B2 (en) 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
CN103898047B (zh) 2003-12-23 2020-03-03 维亚希特公司 定形内胚层
WO2007059007A2 (en) 2005-11-14 2007-05-24 Cythera, Inc. Markers of definitive endoderm
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
EP1791952A4 (en) 2004-08-13 2008-06-11 Univ Georgia Res Found COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS
EP1856526A4 (en) 2005-01-20 2008-11-12 Univ Rochester THIOREDOXIN-INTERACTING PROTEIN (TXNIP) AS REGULATOR OF VASCULAR FUNCTION
AU2006305879B2 (en) 2005-10-27 2012-05-10 Viacyte, Inc. PDX1-expressing dorsal and ventral foregut endoderm
KR20080109775A (ko) 2006-02-23 2008-12-17 노보셀, 인크 분화가능한 세포를 배양하는데 유용한 조성물 및 방법
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
EP1999253B1 (en) 2006-03-02 2019-05-22 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
WO2007139929A2 (en) 2006-05-25 2007-12-06 The Burnham Institute For Medical Research Methods for culture and production of single cell populations of human embryonic stem cells
CA3114827C (en) 2007-07-31 2023-09-05 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic endocrine
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8623650B2 (en) 2007-10-19 2014-01-07 Viacyte, Inc. Methods and compositions for feeder-free pluripotent stem cell media containing human serum
EP2229434B1 (en) 2007-11-27 2011-09-07 Lifescan, Inc. Differentiation of human embryonic stem cells
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
US7939322B2 (en) 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
US20120058105A1 (en) 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications
PL2346988T3 (pl) 2008-10-31 2017-10-31 Janssen Biotech Inc Różnicowanie ludzkich zarodkowych komórek macierzystych do linii endokrynnej trzustki
MX349178B (es) 2008-10-31 2017-07-17 Centocor Ortho Biotech Inc Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático.
US8895300B2 (en) 2008-11-04 2014-11-25 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
AU2009313870B2 (en) 2008-11-14 2013-07-11 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US20100272710A1 (en) * 2009-03-26 2010-10-28 Abdelhadi Rebbaa Compositions and methods for treating and preventing aging-associated diseases
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US20100272695A1 (en) 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
US8685726B2 (en) 2009-04-27 2014-04-01 Viacyte, Inc. Small molecules supporting pluripotent cell growth and methods thereof
EP2456859A4 (en) 2009-07-20 2015-03-18 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
SG177483A1 (en) 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
SG181687A1 (en) 2009-12-23 2012-07-30 Centocor Ortho Biotech Inc Differentiation of human embryonic stem cells
CA2784425A1 (en) 2009-12-23 2011-06-30 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
EP2611907B1 (en) 2010-08-31 2016-05-04 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
ES2658146T3 (es) 2010-08-31 2018-03-08 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas
AU2010365057B2 (en) 2010-12-08 2016-12-22 Viacyte, Inc. Agents and methods for inhibiting human pluripotent stem cell growth
WO2012145384A1 (en) 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
KR102203056B1 (ko) 2011-12-22 2021-01-14 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
ES2615346T3 (es) * 2012-04-25 2017-06-06 Deutsches Krebsforschungszentrum Inhibidores de la proteína que interacciona con tiorredoxina (TXNIP) para terapia
JP6450674B2 (ja) 2012-05-07 2019-01-09 ヤンセン バイオテツク,インコーポレーテツド ヒト胚性幹細胞の膵臓の内胚葉への分化
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
AU2013271581B2 (en) 2012-06-08 2018-08-09 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
EP2861723A4 (en) 2012-06-14 2016-01-20 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONAL STEM CELLS IN ENDOCRINE PANCREAS CELLS
CN105121648B (zh) 2012-12-12 2021-05-07 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
JP6557147B2 (ja) 2012-12-31 2019-08-07 ヤンセン バイオテツク,インコーポレーテツド Hb9調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化
RU2687379C2 (ru) 2012-12-31 2019-05-13 Янссен Байотек, Инк. Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
BR112015015770A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9101597B2 (en) * 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
SG11201510177WA (en) 2013-06-11 2016-01-28 Harvard College SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
KR20140144964A (ko) 2013-06-12 2014-12-22 한국생명공학연구원 티오레독신-결합 단백질을 유효성분으로 포함하는 약학적 조성물 및 이의 용도
KR20250012194A (ko) * 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
KR20160079072A (ko) 2013-11-01 2016-07-05 얀센 바이오테크 인코포레이티드 췌장 내분비 세포로의 분화를 위한 인간 만능 줄기세포의 현탁 및 클러스터링
MX373460B (es) * 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
AU2015363008B2 (en) 2014-12-19 2021-12-09 Janssen Biotech, Inc. Suspension culturing of pluripotent stem cells
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
JP6928604B2 (ja) 2015-11-04 2021-09-01 フェイト セラピューティクス,インコーポレイテッド 万能性細胞のゲノム改変
CN110312799A (zh) 2016-08-17 2019-10-08 博德研究所 新型crispr酶和系统
US9982267B2 (en) 2016-10-12 2018-05-29 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
DK3537986T3 (da) 2016-11-10 2025-07-21 Viacyte Inc Pdx1 pankreatiske endodermceller i celleleveringsanordning
CN110177869A (zh) 2017-01-13 2019-08-27 加利福尼亚大学董事会 免疫改造的多能细胞
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
KR20200075851A (ko) 2017-10-19 2020-06-26 셀렉티스 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
US20190223416A1 (en) 2018-01-23 2019-07-25 Cotyledon, LLC Canine genome editing
EP3754018A4 (en) 2018-02-16 2021-11-24 Kyoto University LOW ANTIGENIC CELL PRODUCTION PROCESS
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
KR20220058579A (ko) 2019-09-05 2022-05-09 크리스퍼 테라퓨틱스 아게 보편적 공여자 세포
US11104918B2 (en) * 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells

Similar Documents

Publication Publication Date Title
CN113423727B (zh) 通用供体细胞
TWI716758B (zh) 初代細胞基因編輯
US20200407693A1 (en) Method for producing low-antigenic cell
US11433103B2 (en) Universal donor cells
US11434505B2 (en) Universal donor cells
KR20220095223A (ko) 조작된 조절 t 세포 생성
JPWO2021044379A5 (https=)
WO2020205759A1 (en) Personalized neoantigen-specific adoptive cell therapies
JPWO2021044377A5 (https=)
US20220279767A1 (en) Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice
Robinson et al. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis—implications for tumor tolerance
KR20230170442A (ko) 내인성 항원 제시 기전을 이용한 저면역원성 줄기세포 및 이의 제조 방법
EP4112720A1 (en) Genetically modified megakaryocyte, modified platelet, and methods respectively for producing said genetically modified megakaryocyte and said modified platelet
CN118792257A (zh) 免疫相容性人胚干细胞及其制备方法
Transfection Lack of Ignorance to Tumor Antigens: Evaluation Using